User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Optimal care of lupus nephritis patients.

Primary tabs

Jadoul, Michel [UCL]

Optimal care of lupus nephritis patients should include the treatment of proteinuria and hypertension, other measures to delay the progression of chronic kidney disease, the vigorous management of cardiovascular risk factors and finally, the treatment of advanced chronic kidney disease and its consequences. These topics are briefly reviewed in the present paper, with particular emphasis on the recent progresses in antiproteinuric treatment.

Document type Article de périodique (Journal article) – Journal Article, Review
Access type Accès restreint
Publication date 2005
Journal information "Lupus" - Vol. 14, no. 1, p. 72-6 (2005)
Peer reviewed yes
issn 0961-2033
Publication status Publié
Affiliations UCL - MD/MINT - Département de médecine interne
UCL - (SLuc) Service de néphrologie
MESH Subject Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Antihypertensive Agents - therapeutic use ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - drug therapy ; Disease Progression ; Humans ; Hypertension - drug therapy ; Immunosuppressive Agents - therapeutic use ; Kidney Failure, Chronic - drug therapy ; Lupus Nephritis - drug therapy ; Patient Care ; Proteinuria - drug therapy - etiology ; Risk Factors
Links
  1. Bjornadal L, Journal of Rheumatology, 31, 713 (2004)
  2. Remuzzi Giuseppe, Bertani Tullio, Pathophysiology of Progressive Nephropathies, 10.1056/nejm199811123392007
  3. Taal Maarten W., Brenner Barry M., Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists, 10.1046/j.1523-1755.2000.00031.x
  4. Lewis Edmund J., Hunsicker Lawrence G., Bain Raymond P., Rohde Richard D, The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy, 10.1056/nejm199311113292004
  5. Maschio Giuseppe, Alberti Daniele, Janin Gérard, Locatelli Francesco, Mann Johannes F.E., Motolese Mario, Ponticelli Claudio, Ritz Eberhard, Zucchelli Pietro, Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency, 10.1056/nejm199604113341502
  6. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, 10.1016/s0140-6736(96)11445-8
  7. Ruggenenti Piero, Perna Annalisa, Gherardi Giulia, Gaspari Flavio, Benini Roberto, Remuzzi Giuseppe, Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial, 10.1016/s0140-6736(98)04433-x
  8. Ruggenenti Piero, Perna Annalisa, Gherardi Giulia, Garini Giovanni, Zoccali Carmine, Salvadori Maurizio, Scolari Francesco, Schena Francesco Paolo, Remuzzi Giuseppe, Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria, 10.1016/s0140-6736(98)10363-x
  9. Lewis Edmund J., Hunsicker Lawrence G., Clarke William R., Berl Tomas, Pohl Marc A., Lewis Julia B., Ritz Eberhard, Atkins Robert C., Rohde Richard, Raz Itamar, Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes, 10.1056/nejmoa011303
  10. Brenner Barry M., Cooper Mark E., de Zeeuw Dick, Keane William F., Mitch William E., Parving Hans-Henrik, Remuzzi Giuseppe, Snapinn Steven M., Zhang Zhonxin, Shahinfar Shahnaz, Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy, 10.1056/nejmoa011161
  11. Jafar Tazeen H., Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease : A Meta-Analysis of Patient-Level Data, 10.7326/0003-4819-135-2-200107170-00007
  12. Campbell Ruth, Sangalli Fabio, Perticucci Elena, Aros Claudio, Viscarra Cecilia, Perna Annalisa, Remuzzi Andrea, Bertocchi Federico, Fagiani Luca, Remuzzi Giuseppe, Ruggenenti Piero, Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies, 10.1046/j.1523-1755.2003.00832.x
  13. Gale E.A.M., European Nicotinamide Diabetes Inte The, Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT), 10.1007/s00125-003-1033-8
  14. DEPARTMENT OF ERROR, 10.1016/s0140-6736(03)12947-9
  15. Ruggenenti Piero, Perna Annalisa, Remuzzi Giuseppe, Investigators of the Gisen Group, Retarding progression of chronic renal disease: The neglected issue of residual proteinuria, 10.1046/j.1523-1755.2003.00033.x
  16. Buter H, The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide, 10.1093/ndt/13.7.1682
  17. Bakris George L., Weir Matthew R., Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine : Is This a Cause for Concern?, 10.1001/archinte.160.5.685
  18. Ruggenenti P., Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies, 10.1161/01.cir.0000047526.08376.80
  19. Houssiau FA, Arthritis Rheum
  20. Bessant R., Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus, 10.1093/rheumatology/keh213
  21. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension* : , 10.1097/00004872-200306000-00001
  22. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., , Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 10.1161/01.hyp.0000107251.49515.c2
  23. Levey Andrew S., Nondiabetic Kidney Disease, 10.1056/nejmcp013462
  24. Bakris George L., Weir Matthew R., Secic Michelle, Campbell Brett, Weis-McNulty Annette, Differential effects of calcium antagonist subclasses on markers of nephropathy progression, 10.1111/j.1523-1755.2004.00620.x
  25. Locatelli F, How long can dialysis be postponed by low protein diet and ACE inhibitors?, 10.1093/ndt/14.6.1360
  26. Wilmer W. A., Management of Glomerular Proteinuria: A Commentary, 10.1097/01.asn.0000100145.27188.33
  27. Klahr Saulo, Levey Andrew S., Beck Gerald J., Caggiula Arlene W., Hunsicker Lawrence, Kusek John W., Striker Gary, The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease, 10.1056/nejm199403313301301
  28. Roman Mary J., Shanker Beth-Ann, Davis Adrienne, Lockshin Michael D., Sammaritano Lisa, Simantov Ronit, Crow Mary K., Schwartz Joseph E., Paget Stephen A., Devereux Richard B., Salmon Jane E., Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus, 10.1056/nejmoa035471
  29. Asanuma Yu, Oeser Annette, Shintani Ayumi K., Turner Elizabeth, Olsen Nancy, Fazio Sergio, Linton MacRae F., Raggi Paolo, Stein C. Michael, Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus, 10.1056/nejmoa035611
  30. Smith C. Richard, Lipid-lowering therapy : New and established agents reduce risk of cardiovascular events, 10.3810/pgm.2004.03.1454
  31. McCarey David W, McInnes Iain B, Madhok Rajan, Hampson Rosie, Scherbakova Olga, Ford Ian, Capell Hilary A, Sattar Naveed, Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial, 10.1016/s0140-6736(04)16449-0
  32. Hahn Bevra Hannahs, Systemic Lupus Erythematosus and Accelerated Atherosclerosis, 10.1056/nejmp038168
  33. Devuyst O., Goffin E., Pirson Y., Van Ypersele De Strihou CH., Creatinine rise after fibrate therapy in renal graft recipients, 10.1016/0140-6736(93)90625-q
  34. Martínez-Berriotxoa Agustín, Ruiz-Irastorza Guillermo, Victoria Egurbide Arberas María, Rueda Gutiérrez Miguel, Aguirre Errasti Ciriaco, Homocisteína plasmática en pacientes con lupus eritematoso sistémico, 10.1016/s0025-7753(03)73812-3
  35. De Vriese An S., Verbeke Francis, Schrijvers Bieke F., Lameire Norbert H., Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?, 10.1046/j.1523-1755.2002.00249.x
  36. Lange Helmut, Suryapranata Harry, De Luca Giuseppe, Börner Caspar, Dille Joep, Kallmayer Klaus, Pasalary M. Noor, Scherer Eberhard, Dambrink Jan-Henk E., Folate Therapy and In-Stent Restenosis after Coronary Stenting, 10.1056/nejmoa032845
  37. Øhlenschlæger Tommy, Garred Peter, Madsen Hans O., Jacobsen Søren, Mannose-Binding Lectin Variant Alleles and the Risk of Arterial Thrombosis in Systemic Lupus Erythematosus, 10.1056/nejmoa033122
  38. Ifudu Onyekachi, Dawood Mohammed, Homel Peter, Friedman Eli A., Excess morbidity in patients starting uremia therapy without prior care by a nephrologist, 10.1016/s0272-6386(96)90383-2
  39. Jungers P, Nephrology Dialysis Transplantation, 8, 1089 (1993)
  40. Kinchen Kraig S., Sadler John, Fink Nancy, Brookmeyer Ronald, Klag Michael J., Levey Andrew S., Powe Neil R., The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality, 10.7326/0003-4819-137-6-200209170-00007
  41. Rippe B., What is the role of albumin in proteinuric glomerulopathies?, 10.1093/ndt/gfg390
  42. Eknoyan Garabed, Lindberg Jill S, On the evolving nature of understanding dialysis-related disorders, 10.1016/s0272-6386(03)00111-2
Bibliographic reference Jadoul, Michel. Optimal care of lupus nephritis patients.. In: Lupus, Vol. 14, no. 1, p. 72-6 (2005)
Permanent URL http://hdl.handle.net/2078.1/10116